Abstract

Abstract Background: Tumor antigens (TA) on cancer cells can trigger immune response TA are peptides that are either not present, or are present to a much lesser extent, on normal cells compared to tumor cells. CD8+ Cytotoxic T-cells (CTL) recognize TAs bound to class I major histocompatibility complex (MHC) molecules on the surface of tumor cells. We and others have shown that viruses subvert the mutational activity of the endogenous DNA-editing APOBEC enzymes in human host cells towards immune escape. Viruses do so by adapting their genomic DNA code to position APOBEC's favored mutational “hotspot” DNA sequences such that upon being mutated by the host APOBEC enzymes, the mutated viral protein is less immunogenic for CTL recognition. Like viruses, cancer cells have genomes that are highly plastic and adaptable through mutation; therefore, we hypothesize that the APOBEC DNA-editing enzymes are exploited by cancer cells for modulating TA immunogenicity. Aims of the Study: Aim1: To elucidate the impact of A3-mediated mutations on modulating TA immunogenicity for CTL recognition. Aim 2: To examine whether genomic sequences encoding TAs in the human genome have co-evolved to either attract or avoid APOBEC-driven mutations. Methods: Aim 1: Using the human reference proteome from EMBL/EBI, we located APOBEC-mutable hotspots in genomic DNA encoding the immunopeptidome. We simulated APOBEC-mediated mutations and translated to peptide TAs. We used NetMHCpan 4 to measure the impact of TA mutations on MHC class I binding affinity. In parallel, we are searching for already-identified APOBEC-mediated mutations in sequenced tumor genomes in cancer genome databases such as The Cancer Genome Atlas (TCGA), Catalogue of Observed Somatic Mutations in Cancer (COSMIC) and International Cancer Genome Consortium (ICGC). Aim 2: To investigate the enrichment of APOBEC-hotspots in genomic sequences encoding TAs restricted to each HLA, we are tabulating APOBEC hotspots in genomic DNA sequencing encoding TAs vs. non-TA-encoding sequences. At the sequence level, the ratio of hotspot frequency, in combination with scores of predicted impacts on immunogenicity as obtained in aim 1, will be used to glean whether and how the human genomic sequence has co-evolved with APOBECs from the standpoint of TAs. Results and Significance: Based on the preliminary data we observe that APOBEC-mediated mutations can diminish or enhance immunogenicity. Understanding the balance between these two effects is key in informing how APOBEC expression and activity ought to be regarded in the context of cancer immunotherapy. Citation Format: Faezeh Borzooee. Examining the role of genome editing enzymes in anti tumor immunity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1483.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.